Analyst Coverage

Cantor Fitzgerald & Co.
Louisa Chen
Citi Investment Research
Yigal Nochomovitz, Ph.D.
Janney Montgomery Scott LLC
Esther Jong, J.D.
JonesTrading Institutional Services LLC
Matthew Cross
Laidlaw & Company Ltd.
Yale Jen, Ph.D
Stifel, Nicolaus & Company, Inc.
Adam Walsh, M.D

Aldeyra Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Aldeyra Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aldeyra Therapeutics, Inc. or its management. Aldeyra Therapeutics, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video